FDA Expands Hympavzi Label to Younger Haemophilia Patients, Boosting Market Potential
PFE•FDA approves Pfizer’s Hympavzi for haemophilia A and B treatment in patients aged 6 and above, including those with inhibitors. Phase III BASIS trials showed a 93% reduction in annualized bleeding rate and interim pediatric data demonstrated improved bleeding outcomes versus historical controls.
1. Expanded Indication Details
The FDA approved Hympavzi for prophylactic treatment of haemophilia A or B in patients aged 12 and older with inhibitors and children aged six to 11, regardless of inhibitor status. The once-weekly subcutaneous injection requires no ongoing laboratory monitoring.
2. Clinical Trial Efficacy Data
Phase III BASIS trial showed a 93% reduction in treated annualized bleeding rate compared to on-demand intravenous agents in adults and adolescents with inhibitors. Interim BASIS KIDS results in patients aged six to 17 demonstrated improved bleeding outcomes versus historical controls.
3. Safety and Precautions
Reported adverse reactions include injection site reactions, headache, fever, joint pain, diarrhea, itching and rash, with two thromboembolic events among 259 extension study patients. Label warnings highlight risks of thromboembolic events, hypersensitivity, embryofetal toxicity and laboratory anomalies.
4. Commercial and Market Impact
The expanded pediatric approval opens a new market segment, particularly for six- to 11-year-olds with haemophilia B who gain first-time access to non-factor subcutaneous treatment. Priority review and breakthrough therapy designations accelerate market entry and could drive revenue growth.
